NCT02235961 is a Phase 1 clinical trial of NNC9204-0530 in Metabolism and Nutrition Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT02235961?

NCT02235961 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT02235961?

Interventions in NCT02235961: NNC9204-0530, liraglutide, placebo.

What condition does NCT02235961 study?

NCT02235961 studies Metabolism and Nutrition Disorder, Obesity.

Is NCT02235961 still recruiting?

NCT02235961 is currently completed. Last updated 27 July 2017.

Last reviewed 2017-07-27 · How we verify

NCT02235961

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Completed Phase 1 Last updated 27 July 2017

What this trial tests

Phase 1 trial testing NNC9204-0530 in Metabolism and Nutrition Disorder in 163 participants. Completed in 6 July 2016.

Timeline

4 September 2014

Primary endpoint
6 July 2016

6 July 2016

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	163
Start date	4 September 2014
Primary completion	6 July 2016
Estimated completion	6 July 2016
Sites	1 location across United States

Drugs / interventions tested

NNC9204-0530 — full drug profile →
liraglutide (liraglutide) — full drug profile →
placebo

Conditions studied

Metabolism and Nutrition Disorder — all drugs for Metabolism and Nutrition Disorder →
Obesity — all drugs for Obesity →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 55, male only, with Metabolism and Nutrition Disorder or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone and in combination with liraglutide in overweight to obese but otherwise healthy male subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The incretin/glucagon system as a target for pharmacotherapy of obesity.
Del Prato S, Gallwitz B, Holst JJ, Meier JJ. · · 2022 · cited 53× · PMID 34713962 · DOI 10.1111/obr.13372

Verify or expand the search:

Other trials of NNC9204-0530

Trials testing the same drug.

NCT02870231 — Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male · Phase 1 · completed
NCT02835235 — A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Bei · Phase 1 · completed

Other recruiting trials for Metabolism and Nutrition Disorder

Currently open trials in the same condition.

NCT05785221 — Energy Metabolism Profiles Over Weight-loss and Eating Responses · NA · active not recruiting
NCT03669809 — The Biological Rhythm of Human Metabolite · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02235961 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 27 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02235961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing